Cannabinoid Drugs

GW Pharmaceuticals PLC (NASDAQ: GWPH)'s stock gained more than 17 percent Monday following the company's announcement of a second successful pivotal trial in an ongoing Phase 3 trial exploring its lead cannabinoid product, Epidiolex. GW Pharma's strong gains helped boost shares of...

Shares of GW Pharmaceuticals PLC (NASDAQ: GWPH) were trading higher by more than 17 percent Monday, but analysts at Cantor Fitzgerald believe the surge has just begun. GW Pharma announced a second successful pivotal trial in an ongoing Phase 3 trial which explores Epidiolex, its lead...

Shares of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a developer of cannabinoid prescription medicines, spiked by more than 10 percent Monday morning following the company's announcement that Epidiolex achieved a primary endpoint in a Phase 3 clinical study. Epidiolex, GW Pharma's lead...